Schroder Investment Management Group lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 27.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 24,160 shares of the pharmaceutical company’s stock after selling 9,238 shares during the quarter. Schroder Investment Management Group’s holdings in Vertex Pharmaceuticals were worth $3,615,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Jennison Associates LLC grew its holdings in shares of Vertex Pharmaceuticals by 253.8% during the second quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock valued at $651,454,000 after buying an additional 3,626,368 shares during the last quarter. Old Mutual Global Investors UK Ltd. lifted its position in Vertex Pharmaceuticals by 1,384.7% during the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,195,455 shares of the pharmaceutical company’s stock valued at $154,058,000 after purchasing an additional 1,114,939 shares during the period. Assenagon Asset Management S.A. lifted its position in Vertex Pharmaceuticals by 9,422.3% during the third quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock valued at $135,829,000 after purchasing an additional 883,998 shares during the period. AJO LP bought a new position in Vertex Pharmaceuticals during the second quarter valued at approximately $71,956,000. Finally, Vanguard Group Inc. lifted its position in Vertex Pharmaceuticals by 3.1% during the second quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock valued at $2,188,196,000 after purchasing an additional 504,982 shares during the period. Institutional investors and hedge funds own 93.33% of the company’s stock.

Vertex Pharmaceuticals Incorporated (VRTX) opened at $140.91 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $167.85. The firm has a market cap of $35,831.27, a P/E ratio of 236.13, a price-to-earnings-growth ratio of 3.39 and a beta of 1.58.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business had revenue of $578.20 million for the quarter, compared to the consensus estimate of $522.07 million. During the same period last year, the firm earned $0.16 earnings per share. The company’s quarterly revenue was up 39.7% on a year-over-year basis. sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.

A number of research analysts recently weighed in on VRTX shares. BidaskClub downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 19th. Jefferies Group restated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 22nd. Vetr downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price objective on the stock. in a research report on Monday, September 4th. Royal Bank of Canada started coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $175.00 price objective on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $195.00 price objective on shares of Vertex Pharmaceuticals in a research report on Sunday, September 17th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-four have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $173.15.

In other news, CEO Jeffrey M. Leiden sold 125,000 shares of the stock in a transaction on Monday, December 11th. The shares were sold at an average price of $141.35, for a total value of $17,668,750.00. Following the completion of the sale, the chief executive officer now directly owns 237,407 shares of the company’s stock, valued at $33,557,479.45. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CMO Jeffrey Chodakewitz sold 3,437 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $151.64, for a total transaction of $521,186.68. The disclosure for this sale can be found here. Insiders sold 343,519 shares of company stock worth $49,488,660 over the last quarter. Insiders own 1.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/schroder-investment-management-group-sells-9238-shares-of-vertex-pharmaceuticals-incorporated-vrtx/1761081.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.